Damora Therapeutics, Inc.

Damora Announces Redomestication from Delaware to Cayman Islands

2026-07-17 08:00:00

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the completion of the redomestication of the Company from the State of Delaware to the Cayman Islands, effective on July 16, 2026. Each outstanding share of the Delaware Company's common stock automatically converted into one ordinary share, par value $0.00001 per share, of the Company, and each outstanding share of any series of the Delaware Company's preferred stock automatically converted into one outstanding share of the corresponding series of the preferred shares of the Company. The redomestication was previously approved by the Company's board of directors and subsequently approved by the stockholders of the Company at a Special Meeting of Stockholders held on February 9, 2026.

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-07-01 16:01:00

BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-01 08:00:00

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on June 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

Damora Therapeutics: Well-Funded Moonshot For CALR Mutations

2026-05-27 07:22:57

Damora Therapeutics is focused on mutant-CALR blood diseases, with DMR-001 as its lead asset. They have approximately $562.3 million in cash, and management believes this gives them enough runway into 2029. DMRA's lead asset has potential competitors in more advanced R&D stages. This helps validate the asset class as a whole, but DMRA still needs more data of its own.

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

2026-05-12 16:05:00

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress – – On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively – – Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms – – Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected to fund operations into 2029 – BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (“Damora” or the “Company”) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the quarter ended March 31, 2026, and recent corporate highlights. “We are pleased with our meaningful progress in advancing our mutant calreticulin (mutCALR)-targeted therapy pipeline, including three highly differentiated assets with distinct mechanisms that uniquely position Damora to drive innovation across all forms of mutCALR-driven disease,” said Jennifer Jarrett, President and Chief Executive Officer of Damora Therapeutics.

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-01 08:00:00

BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to two newly-hired, non-executive employees. The inducement grants were approved by Damora's independent Compensation Committee and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).